糖尿病影响长期护理机构老年居民对SARS-CoV-2疫苗接种的抗体反应:来自GeroCovid Vax研究的数据
GeroCovid Vax研究纳入555名长期护理机构老年居民,评估糖尿病对SARS-CoV-2疫苗抗体反应的影响。线性混合模型显示,糖尿病与首次接种后2个月(β=-0.20;95%CI -0.34,-0.06)和6个月(β=-0.22;95%CI -0.37,-0.07)抗S IgG水平较低相关。未使用胰岛素的糖尿病居民在2个月和6个月时IgG水平较低,而使用胰岛素者未见差异。
要点
- 糖尿病与长期护理机构老年居民接种SARS-CoV-2疫苗后2个月和6个月抗S IgG水平较低相关。
- 未使用胰岛素的糖尿病居民在2个月和6个月时IgG水平较低。
- 使用胰岛素的糖尿病居民抗体反应与无糖尿病者未见差异。
核心结论
- 长期护理机构老年居民中,糖尿病倾向于对COVID-19疫苗接种产生较弱的抗体反应。
- 胰岛素治疗可能缓冲这一效应,并建立与无糖尿病个体相似的体液免疫。
研究设计与样本
- GeroCovid Vax研究分析,纳入555名长期护理机构老年居民。
- 采用化学发光法检测首次接种前及接种后2个月和6个月的SARS-CoV-2三聚体S免疫球蛋白G(抗S IgG)浓度。
- 使用线性混合模型评估糖尿病对抗S IgG水平的影响,模型包括时间与糖尿病存在的交互作用;第二个模型考虑糖尿病治疗:无胰岛素治疗(仅饮食或使用口服降糖药)和胰岛素治疗(单独或联合口服降糖药)。
主要发现
- 样本平均年龄82.1岁,女性占68.1%,25.2%患有糖尿病。
- 线性混合模型中,糖尿病与首次接种后2个月(β=-0.20;95%CI -0.34,-0.06)和6个月(β=-0.22;95%CI -0.37,-0.07)抗S IgG水平较低相关。
- 与无糖尿病者相比,未使用胰岛素的糖尿病居民在2个月和6个月评估时IgG水平较低(β=-0.24;95%CI -0.43,-0.05和β=-0.30;95%CI -0.50,-0.10),而使用胰岛素者未见差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes may affect the humoral immune response after vaccination, but data concerning coronavirus disease 19 (COVID-19) vaccines are scarce. We evaluated the impact of diabetes on antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in older residents of long-term care facilities (LTCFs) and tested for differences according to antidiabetic treatment. RESEARCH DESIGN AND METHODS: For this analysis, 555 older residents of LTCFs participating in the GeroCovid Vax study were included. SARS-CoV-2 trimeric S immunoglobulin G (anti-S IgG) concentrations using chemiluminescent assays were tested before the first dose and after 2 and 6 months. The impact of diabetes on anti-S IgG levels was evaluated using linear mixed models, which included the interaction between time and presence of diabetes. A second model also considered diabetes treatment: no insulin therapy (including dietary only or use of oral antidiabetic agents) and insulin therapy (alone or in combination with oral antidiabetic agents). RESULTS: The mean age of the sample was 82.1 years, 68.1% were women, and 25.2% had diabetes. In linear mixed models, presence of diabetes was associated with lower anti-S IgG levels at 2 (β = -0.20; 95% CI -0.34, -0.06) and 6 months (β = -0.22; 95% CI -0.37, -0.07) after the first vaccine dose. Compared with those without diabetes, residents with diabetes not using insulin had lower IgG levels at 2- and 6-month assessments (β = -0.24; 95% CI -0.43, -0.05 and β = -0.30; 95% CI -0.50, -0.10, respectively), whereas no differences were observed for those using insulin. CONCLUSIONS: Older residents of LTCFs with diabetes tended to have weaker antibody response to COVID-19 vaccination. Insulin treatment might buffer this effect and establish humoral immunity similar to that in individuals without diabetes.
引用
- Virgilio E, Trevisan C, Abbatecola A, et al. Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-term Care Facilities: Data From the GeroCovid Vax Study. Diabetes Care. 2022. PMID: 36201657. doi:10.2337/dc22-1255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。